Letter to FDA Opposing Approval of Liraglutide (Victoza) for Cardiovascular Risk Reduction

July, 18, 2017

View as PDF.

View June 20, 2017 testimony.

In a letter to the Food and Drug Administration (FDA), Public Citizen urged the FDA not to approve liraglutide (Victoza) for the additional indication of reducing cardiovascular risk in type 2 diabetes patients because the clinical trial to support such approval failed to show any benefit in the 2,500 U.S. subjects in the trial. The study only showed a significant benefit in non-U.S. subjects.

View Public Citizen’s previous work on liraglutide.